pdf   xlsx method abbreviations

la/mBC - HER2 positive - 2nd Line (L2), antibody–drug conjugate , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.65 [0.54, 0.79]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatecrucial-
deaths (OS) (extension) 0.75 [0.64, 0.88]< 10%1 study (1/-)100.0 %NAnot evaluable important-
progression or deaths (PFS) 0.43 [0.19, 0.98]< 196%2 studies (2/-)97.8 %some concernnot evaluable moderateimportant-
objective responses (ORR) 1.73 [1.29, 2.32]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.